The histamine H3 receptor as a therapeutic drug target for CNS disorders
Mark J. Gemkow(Evotec (Germany)), David J. Hallett(Evotec (United Kingdom)), Andrea M. Cesura(Evotec (Germany)), Silke Harich(Evotec (Germany)), Adam J. Davenport(Evotec (United Kingdom)), Bart Ellenbroek(Evotec (Germany))
Cited by 181
Related Papers
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
|Scientific Reports|2021|68
Chiral pyridylimidazolines: synthesis, arene ruthenium complexes and application in asymmetric catalysis
|Journal of the Chemical Society Perkin Transactions 1|2001|67
Arene ruthenium complexes with pyridyloxazolines: synthesis and applications as asymmetric catalysts for Diels–Alder reactions †
|Journal of the Chemical Society Dalton Transactions|2000|66
Arene–ruthenium complexes with salicyloxazolines: diastereoselective synthesis, configurational stability and applications as asymmetric catalysts for Diels–Alder reactions
|Dalton Transactions|2004|61
Synthesis of chiral half-sandwich rhodium oxazoline complexes and their use as asymmetric Diels–Alder catalysts
|Chemical Communications|1997|44